Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

361

WORD

343

HTML

3151

Tables (1-1)

210

Sum=4065

Publishing Process of This Article

Item

Count

Browse

1157

Download

1143

Sum=2300

Oct 10, 2014 (publication date) through Nov 28, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Clin Oncol. Oct 10, 2014; 5(4): 560-567
Published online Oct 10, 2014. doi: 10.5306/wjco.v5.i4.560

Table 1 Drugs that may lower serum levels of targeted therapies

Erlotinib/gefitinib	Afatinib
Rifampin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine, St. John’s wort, proton pump inhibitors, H2-blockers, antacids, tobacco	Rifampin, phenytoin, carbamazepine, St. John’s wort, primidone, tipranavir

Citation: Becker K, Xu Y. Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation. World J Clin Oncol 2014; 5(4): 560-567
URL: https://www.wjgnet.com/2218-4333/full/v5/i4/560.htm
DOI: https://dx.doi.org/10.5306/wjco.v5.i4.560